Copyright
©The Author(s) 2018.
World J Gastroenterol. Dec 7, 2018; 24(45): 5144-5153
Published online Dec 7, 2018. doi: 10.3748/wjg.v24.i45.5144
Published online Dec 7, 2018. doi: 10.3748/wjg.v24.i45.5144
Table 3 Pathological outcomes and survival n (%)
Variable | Value |
pT | |
Tx | 2 (2.4) |
T0 | 1 (1.2) |
T2 | 2 (2.4) |
T3a,b | 6 (7.3) |
T3c,d | 13 (15.9) |
T4a | 27 (32.9) |
T4b | 30 (36.6) |
Missing | 1 (1.2) |
pN | |
Nx | 25 (30.5) |
N0 | 33 (40.2) |
N1 | 17 (20.7) |
N2 | 6 (7.3) |
Missing | 1 (1.2) |
Nodes isolated | 15.5 (10.6) |
Positive nodes | 1.1 (0.4) |
Resection margins involved | 19 (23.2) |
Response to neoadjuvant treatment (n = 59) | |
Complete | 1 (1.7) |
Islands of tumour cells | 1 (1.7) |
Predominantly fibrotic | 20 (33.9) |
Predominantly tumour nests | 21 (35.6) |
No response | 12 (20.3) |
Missing | 4 (6.8) |
Quality of mesorectum[20-23] | |
Good/complete | 61 (74.4) |
Partially good/near complete | 9 (11) |
Bad/incomplete | 8 (9.8) |
Missing | 4 (4.9) |
- Citation: Pellino G, Biondo S, Codina Cazador A, Enríquez-Navascues JM, Espín-Basany E, Roig-Vila JV, García-Granero E, on behalf of the Rectal Cancer Project. Pelvic exenterations for primary rectal cancer: Analysis from a 10-year national prospective database. World J Gastroenterol 2018; 24(45): 5144-5153
- URL: https://www.wjgnet.com/1007-9327/full/v24/i45/5144.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i45.5144